Ann: Kazia announces change to Board of Directors, page-19

I personally don’t argue the path the company has chosen with low overall overhead with few employees and relying on third parties for the execution of the studies. Because of this structure the level of the compensation for the CEO and the Board is high based on this path in terms what they need to do while we wait for results. In terms of filing an NDA when and if we have success with the trials I think you can buy on the market like other contracted services. I personally think this is a better route as you don’t file NDAs everyday and I suspect it requires expert skills to meet all of the FDA requirements and you don’t want delays and failures due to incorrect filing. I suspect there are specialists out there that provide this service. I have seen this with other companies with their own internal expertise and they file incorrectly which creates months and months and even a year delay as you get punted back of the line for the FDA review.

We just need timely results and we have failed to date to meet this need and the price and low liquidity reflects this both on the ASX and Nasdaq. Even though has some liquidity but it is not what it should be considering all of the studies underway.

In another post it was referenced that JG did do interviews and I agree with that but the mkt wants results from studies to back up commentary and that has not happened.